Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas.
Factors associated with poor glycemic control in children with type 1 diabetes generally vary according to the insulin regimen used, but family conflict over diabetes management universally impacts all insulin users, US researchers report.
WATCH | Nephrologist Katherine Tuttle and Primary Care Physician Jay Shubrook discuss referrals to nephrology for patients with comorbid diabetes and kidney disease (8:38).
Researchers have used exome-wide sequencing to identify several rare variants within four genes that are significantly associated with type 2 diabetes.
A small study suggests that the vasodilation effects of aspirin may be delayed in people with type 2 diabetes, and may wear off faster than in people without the condition.
Even with newer devices, continuous glucose monitoring underestimates the fall in glucose levels during exercise, with the drop lagging significantly behind that measured by self-monitoring of blood glucose, research shows.
Hospitalized individuals with diabetes who have low blood glucose levels on the day of discharge have an elevated risk for readmission and death, findings from a large US cohort study suggest.
Type 2 diabetes remission can be achieved within 1 year at a cost below the average annual cost of diabetes management, even when including complications, shows an economic evaluation of the DiRECT/Counterweight-Plus weight management program.
Rates of age-standardized all-cause mortality due to diabetes as the underlying or contributing cause of death have plateaued in recent years following earlier declines, shows an analysis of data from the US Census and national mortality database.
Fournier gangrene remains very rare, but is more common in people using SGLT2 inhibitors compared with other diabetes medications and has severe consequences, shows research.
DIY closed-loop insulin delivery has provoked controversy within the diabetes community, raising questions around patient empowerment, safety and liability, and whether the regulatory process remains fit for purpose in a technological age. medwireNews takes a look at the issues.
Editorial Board member Lori Berard discusses how the ambulatory glucose profile is quietly revolutionizing the analysis of blood glucose and glycemic control for patients and practitioners.
In this video interview, diabetes specialist John Wilding discusses how the CREDENCE trial findings may impact the treatment of people with type 2 diabetes and chronic kidney disease (3:31).
